No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study.
暂无分享,去创建一个
Alison M Dunning | Caroline Baynes | Neil G Burnet | Gillian C Barnett | Catharine M L West | A. Dunning | P. Pharoah | C. Baynes | C. Coles | C. West | N. Burnet | G. Barnett | R. Elliott | Charlotte E Coles | Paul D P Pharoah | Rebecca M Elliott | Jennifer Wilkinson | J. Wilkinson
[1] M. Yokota,et al. Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. , 2000, Circulation.
[2] H. Ostrer,et al. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. , 2008, International journal of radiation oncology, biology, physics.
[3] M. Anscher,et al. Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer? , 2006, Cytokine.
[4] S. Bentzen. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology , 2006, Nature Reviews Cancer.
[5] K. Boda,et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. , 2007, International journal of radiation oncology, biology, physics.
[6] M. Dewhirst,et al. Radiation-induced hypoxia may perpetuate late normal tissue injury. , 2001, International journal of radiation oncology, biology, physics.
[7] J. Coggle,et al. Expression of transforming growth factor-beta 1 in mouse skin during the acute phase of radiation damage. , 1995, International journal of radiation biology.
[8] H. Groen,et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] C. Coles,et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] M. Dewhirst,et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. , 2005, International journal of radiation oncology, biology, physics.
[11] J. Chang-Claude,et al. A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer , 2003 .
[12] K. Cowan,et al. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] J. Peacock,et al. Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. , 2003, International journal of radiation oncology, biology, physics.
[14] J. Lefaix,et al. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] Mary Helen Barcellos-Hoff,et al. Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. , 2002, Cancer research.
[16] J. Yarnold,et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet. Oncology.
[17] M. Anscher,et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. , 1997, International journal of radiation oncology, biology, physics.
[18] Alison M. Dunning,et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype , 2009, Nature Reviews Cancer.
[19] N G Burnet,et al. Radiosensitivity, radiogenomics and RAPPER. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).
[20] N. Aaronson,et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Barcellos-Hoff. Integrative radiation carcinogenesis: interactions between cell and tissue responses to DNA damage. , 2005, Seminars in cancer biology.
[22] H. Thames,et al. Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] D. Tait,et al. Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).
[24] C. Hurley,et al. A molecular mechanism for the differential regulation of TGF-β1 expression due to the common SNP −509C-T (c. −1347C > T) , 2006, Human Genetics.
[25] L. Le Marchand,et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. , 2008, Cancer research.
[26] R. Clough,et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. , 2001, International journal of radiation oncology, biology, physics.
[27] J. Yarnold,et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[28] T. Spector,et al. Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.
[29] J. Alsner,et al. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] J. Overgaard,et al. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[31] J R Yarnold,et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.
[32] J Nyman,et al. Prognostic factors for acute and late skin reactions in radiotherapy patients. , 1996, International journal of radiation oncology, biology, physics.
[33] M. Bissell,et al. Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. , 2007, Cancer research.
[34] S. Kumar,et al. TGF‐β1 levels in pre‐treatment plasma identify breast cancer patients at risk of developing post‐radiotherapy fibrosis , 1999, International journal of cancer.
[35] M. Martin,et al. Coactivation of AP-1 activity and TGF-β1 gene expression in the stress response of normal skin cells to ionizing radiation , 1997, Oncogene.
[36] F. B. Sørensen,et al. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATMndash; a study based on DNA from formalin fixed paraffin embedded tissue samples , 2006, International journal of radiation biology.
[37] A. Hajeer,et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients , 2003, International journal of radiation biology.
[38] I. Turesson. Individual variation and dose dependency in the progression rate of skin telangiectasia. , 1990, International journal of radiation oncology, biology, physics.
[39] M. Plumb,et al. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes , 2007, British Journal of Cancer.
[40] M. Barcellos-Hoff,et al. Latent transforming growth factor β1 activation in situ: quantitative and functional evidence after low‐dose γ‐irradiation 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] H. Thierens,et al. TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. , 2006, International journal of radiation oncology, biology, physics.